GenSight Biologics reports first-half 2026 results, provides business updates

The company said cash collected from paid early access programs was €6.5 million and net cash used in operating activities fell 37% to €1.6 million. It also said manufacturing technology transfer to Catalent was completed and REVISE remains on track for a December 2026 last patient.